Is Liver Biopsy a Gold or an Old Standard in NAFL and NASH?

Examining liver biopsy as a benchmark test in NASH/NAFL trials

Read more

In this International Biopharmaceutical Industry article, Scott Beasley and Rafal Ziecina M.D., Ph.D., discuss how non-invasive imaging is replacing liver biopsy as the gold standard for evaluation of fibrosis in non-alcoholic fatty liver disease (NAFLD) and NASH for clinical trials.


Executive Director, Project Management, MASH
Executive Director, Scientific Solutions, Cardiovascular, Endocrine & Metabolic

Want to learn more about Worldwide Clinical Trials?